当前位置: 首页 >> 检索结果
1. Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial.
作者: S C van Doorn.;M van der Vlugt.;Actm Depla.;C A Wientjes.;R C Mallant-Hent.;P D Siersema.;Kmaj Tytgat.;H Tuynman.;S D Kuiken.;Gmp Houben.;Pcf Stokkers.;Lmg Moons.;Pmm Bossuyt.;P Fockens.;M W Mundt.;E Dekker.
来源: Gut. 2017年66卷3期438-445页
Colonoscopy is the current reference standard for the detection of colorectal neoplasia, but nevertheless adenomas remain undetected. The Endocuff, an endoscopic cap with plastic projections, may improve colonic visualisation and adenoma detection. The aim of this study was to compare the mean number of adenomas per patient (MAP) and the adenoma detection rate (ADR) between Endocuff-assisted colonoscopy (EAC) and conventional colonoscopy (CC).
2. Split-dose preparation for colonoscopy increases adenoma detection rate: a randomised controlled trial in an organised screening programme.
作者: F Radaelli.;S Paggi.;C Hassan.;C Senore.;R Fasoli.;A Anderloni.;F Buffoli.;M F Savarese.;G Spinzi.;D K Rex.;A Repici.
来源: Gut. 2017年66卷2期270-277页
Although a split regimen of bowel preparation has been associated with higher levels of bowel cleansing, it is still uncertain whether it has a favourable effect on the adenoma detection rate (ADR). The present study was aimed at evaluating whether a split regimen was superior to the traditional 'full-dose, day-before' regimen in terms of ADR.
3. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery.
作者: S Mondot.;P Lepage.;P Seksik.;M Allez.;X Tréton.;Y Bouhnik.;J F Colombel.;M Leclerc.;P Pochart.;J Doré.;P Marteau.; .
来源: Gut. 2016年65卷6期954-62页
Preventing postoperative recurrence after ileocolonic resection (ICR) for Crohn's disease (CD) is challenging. Defining the disturbances of the microbial composition and community structure after ICR and their link with early disease recurrence is crucial.
4. Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.
作者: An Moonen.;Vito Annese.;Ann Belmans.;Albert J Bredenoord.;Stanislas Bruley des Varannes.;Mario Costantini.;Bertrand Dousset.;J I Elizalde.;Uberto Fumagalli.;Marianne Gaudric.;Antonio Merla.;Andre J Smout.;Jan Tack.;Giovanni Zaninotto.;Olivier R Busch.;Guy E Boeckxstaens.
来源: Gut. 2016年65卷5期732-9页
Achalasia is a chronic motility disorder of the oesophagus for which laparoscopic Heller myotomy (LHM) and endoscopic pneumodilation (PD) are the most commonly used treatments. However, prospective data comparing their long-term efficacy is lacking.
5. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease.
作者: Aranzazu Jauregui-Amezaga.;Montserrat Rovira.;Pedro Marín.;Azucena Salas.;Susana Pinó-Donnay.;Faust Feu.;J Ignasi Elizalde.;Francesc Fernández-Avilés.;Carmen Martínez.;Gonzalo Gutiérrez.;Laura Rosiñol.;Enric Carreras.;Alvaro Urbano.;Miguel Lozano.;Joan Cid.;María Suárez-Lledó.;Josep Mensa.;Jordi Rimola.;Sonia Rodríguez.;Mari Carme Masamunt.;Dolors Comas.;Irene Ruíz.;Anna Ramírez-Morros.;Marta Gallego.;Ingrid Ordás.;Julian Panés.;Elena Ricart.
来源: Gut. 2016年65卷9期1456-62页
To evaluate the feasibility and toxicity of autologous haematopoietic stem cell transplantation (HSCT) for the treatment of refractory Crohn's disease (CD).
6. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.
作者: Hemant K Roy.;Vladimir Turzhitsky.;Ramesh Wali.;Andrew J Radosevich.;Borko Jovanovic.;Gary Della'Zanna.;Asad Umar.;David T Rubin.;Michael J Goldberg.;Laura Bianchi.;Mart De La Cruz.;Andrej Bogojevic.;Irene B Helenowski.;Luz Rodriguez.;Robert Chatterton.;Silvia Skripkauskas.;Katherine Page.;Christopher R Weber.;Xiaoke Huang.;Ellen Richmond.;Raymond C Bergan.;Vadim Backman.
来源: Gut. 2017年66卷2期285-292页
A major impediment to translating chemoprevention to clinical practice has been lack of intermediate biomarkers. We previously reported that rectal interrogation with low-coherence enhanced backscattering spectroscopy (LEBS) detected microarchitectural manifestations of field carcinogenesis. We now wanted to ascertain if reversion of two LEBS markers spectral slope (SPEC) and fractal dimension (FRAC) could serve as a marker for chemopreventive efficacy.
7. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.
作者: Jyh-Ming Liou.;Chieh-Chang Chen.;Chi-Yang Chang.;Mei-Jyh Chen.;Chien-Chuan Chen.;Yu-Jen Fang.;Ji-Yuh Lee.;Tsung-Hua Yang.;Jiing-Chyuan Luo.;Jeng-Yih Wu.;Tai-Cherng Liou.;Wen-Hsiung Chang.;Yao-Chun Hsu.;Cheng-Hao Tseng.;Chun-Chao Chang.;Ming-Jong Bair.;Tzeng-Ying Liu.;Chun-Fu Hsieh.;Feng-Yun Tsao.;Chia-Tung Shun.;Jaw-Town Lin.;Yi-Chia Lee.;Ming-Shiang Wu.; .
来源: Gut. 2016年65卷11期1784-1792页
Significant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy for 14 days (T14) in the first-line treatment of Helicobacter pylori. We aimed to compare the efficacy of S10 and T14 and assess the factors affecting their efficacies.
8. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
作者: Wei Zhang.;Qi Chen.;Xiao Liang.;Wenzhong Liu.;Shudong Xiao.;David Y Graham.;Hong Lu.
来源: Gut. 2015年64卷11期1715-20页
To evaluate the efficacy and tolerability of replacing tetracycline with amoxicillin in bismuth quadruple therapy.
9. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication.
作者: Kai-feng Pan.;Lian Zhang.;Markus Gerhard.;Jun-ling Ma.;Wei-dong Liu.;Kurt Ulm.;Jian-xi Wang.;Lei Zhang.;Yang Zhang.;Monther Bajbouj.;Lan-fu Zhang.;Ming Li.;Michael Vieth.;Rui-yong Liu.;Michael Quante.;Le-hua Wang.;Stepan Suchanek.;Tong Zhou.;Wei-xiang Guan.;Roland Schmid.;Meinhard Classen.;Wei-cheng You.
来源: Gut. 2016年65卷1期9-18页
To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China.
10. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.
作者: Reena Khanna.;Guangyong Zou.;Geert D'Haens.;Paul Rutgeerts.;J W D McDonald.;Marco Daperno.;Brian G Feagan.;William J Sandborn.;Elena Dubcenco.;Larry Stitt.;Margaret K Vandervoort.;Allan Donner.;Allison Luo.;Barrett G Levesque.
来源: Gut. 2016年65卷7期1119-25页
The Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to assess Crohn's disease (CD) activity; however, neither instrument has been fully validated. We assessed intra-rater and inter-rater reliability of these indices.
11. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
作者: Young-Suk Lim.;Byung Chul Yoo.;Kwan Soo Byun.;So Young Kwon.;Yoon Jun Kim.;Jihyun An.;Han Chu Lee.;Yung Sang Lee.
来源: Gut. 2016年65卷6期1042-51页
Little clinical data are available regarding the optimal treatment of patients who harbour adefovir-resistant HBV.
12. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
作者: Stephan Miehlke.;Petr Hruz.;Michael Vieth.;Christian Bussmann.;Ulrike von Arnim.;Monther Bajbouj.;Christoph Schlag.;Ahmed Madisch.;Christiane Fibbe.;Henning Wittenburg.;Hans Dieter Allescher.;Max Reinshagen.;Stefan Schubert.;Jan Tack.;Michaela Müller.;Patrick Krummenerl.;Joris Arts.;Ralph Mueller.;Karin Dilger.;Roland Greinwald.;Alex Straumann.
来源: Gut. 2016年65卷3期390-9页
To investigate the efficacy and safety of two different budesonide formulations (effervescent tablet for orodispersible use (BET) and viscous suspension (BVS)) with different daily dosages for short-term treatment of eosinophilic oesophagitis (EoE).
13. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
作者: Patrick M Lynch.;Carol A Burke.;Robin Phillips.;Jeffrey S Morris.;Rebecca Slack.;Xuemei Wang.;Jun Liu.;Sherri Patterson.;Frank A Sinicrope.;Miguel A Rodriguez-Bigas.;Elizabeth Half.;Steffen Bulow.;Andrew Latchford.;Sue Clark.;William A Ross.;Bonnie Malone.;Hennie Hasson.;Ellen Richmond.;Ernest Hawk.
来源: Gut. 2016年65卷2期286-95页
Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.
14. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
作者: Ching Lam.;Wei Tan.;Matthew Leighton.;Margaret Hastings.;Melanie Lingaya.;Yirga Falcone.;Xiaoying Zhou.;Luting Xu.;Peter Whorwell.;Andrew F Walls.;Abed Zaitoun.;Alan Montgomery.;Robin Spiller.
来源: Gut. 2016年65卷1期91-9页
Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 months in patients with Rome III criteria IBS-D. Primary outcome was daily average stool frequency during weeks 11-12; secondary outcomes were abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms.
15. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial.
作者: Michal F Kaminski.;John Anderson.;Roland Valori.;Ewa Kraszewska.;Maciej Rupinski.;Jacek Pachlewski.;Ewa Wronska.;Michael Bretthauer.;Siwan Thomas-Gibson.;Ernst J Kuipers.;Jaroslaw Regula.
来源: Gut. 2016年65卷4期616-24页
Suboptimal adenoma detection rate (ADR) at colonoscopy is associated with increased risk of interval colorectal cancer. It is uncertain how ADR might be improved. We compared the effect of leadership training versus feedback only on colonoscopy quality in a countrywide randomised trial.
16. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
作者: Young-Suk Lim.;Kwan Soo Byun.;Byung Chul Yoo.;So Young Kwon.;Yoon Jun Kim.;Jihyun An.;Han Chu Lee.;Yung Sang Lee.
来源: Gut. 2016年65卷5期852-60页
Little clinical data are available regarding the optimal treatment of patients who harbour entecavir (ETV)-resistant HBV.
17. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
作者: Rong Fan.;Jian Sun.;Quan Yuan.;Qing Xie.;Xuefan Bai.;Qin Ning.;Jun Cheng.;Yanyan Yu.;Junqi Niu.;Guangfeng Shi.;Hao Wang.;Deming Tan.;Mobin Wan.;Shijun Chen.;Min Xu.;Xinyue Chen.;Hong Tang.;Jifang Sheng.;Fengmin Lu.;Jidong Jia.;Hui Zhuang.;Ningshao Xia.;Jinlin Hou.; .
来源: Gut. 2016年65卷2期313-20页
The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic hepatitis B (CHB) treatment is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively.
18. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
作者: Walter Reinisch.;Julián Panés.;Sunil Khurana.;Gabor Toth.;Fei Hua.;Gail M Comer.;Michelle Hinz.;Karen Page.;Margot O'Toole.;Tara McDonnell Moorehead.;Hua Zhu.;YanHui Sun.;Fabio Cataldi.
来源: Gut. 2015年64卷6期894-900页
Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC.
19. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry.
作者: R J Haidry.;M A Butt.;J M Dunn.;A Gupta.;G Lipman.;H L Smart.;P Bhandari.;L Smith.;R Willert.;G Fullarton.;M Di Pietro.;C Gordon.;I Penman.;H Barr.;P Patel.;N Kapoor.;J Hoare.;R Narayanasamy.;Y Ang.;A Veitch.;K Ragunath.;M Novelli.;L B Lovat.; .
来源: Gut. 2015年64卷8期1192-9页
Barrett's oesophagus (BE) is a pre-malignant condition leading to oesophageal adenocarcinoma (OAC). Treatment of neoplasia at an early stage is desirable. Combined endoscopic mucosal resection (EMR) followed by radiofrequency ablation (RFA) is an alternative to surgery for patients with BE-related neoplasia.
20. Randomised controlled trial of mesalazine in IBS.
作者: Giovanni Barbara.;Cesare Cremon.;Vito Annese.;Guido Basilisco.;Franco Bazzoli.;Massimo Bellini.;Antonio Benedetti.;Luigi Benini.;Fabrizio Bossa.;Paola Buldrini.;Michele Cicala.;Rosario Cuomo.;Bastianello Germanà.;Paola Molteni.;Matteo Neri.;Marcello Rodi.;Alfredo Saggioro.;Maria Lia Scribano.;Maurizio Vecchi.;Giorgio Zoli.;Roberto Corinaldesi.;Vincenzo Stanghellini.
来源: Gut. 2016年65卷1期82-90页
Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. In this trial, we aimed at evaluating the efficacy and safety of mesalazine in patients with IBS.
|